Objectives: Because genetic polymorphisms cause diverse activity in drug metabolizing enzymes, drug concentrations in the blood may be variable among patients. We analyzed the genotypes of CYP3A5 and MDR1, and investigated their relationship with whole blood drug concentrations.
Introduction
Calcineurin inhibitors, such as tacrolimus and cyclosporine, are specific inhibitors for calcineurin, which is a dephosphorylation enzyme of T cells. These inhibitors have been used as therapies for various diseases. (Table 1) , and food intake such as grapefruits. Recently, the influence of genetic polymorphisms of metabolizing enzymes has also been suggested.
Tacrolimus is metabolized by cytochrome P450 3A4 6, 7 .
In this study, we analyzed genetic polymorphisms in CYP3A5 and MDR1 genes in patients with autoimmune disease, and investigated their relationship with tacrolimus blood concentrations.
Materials and Methods
Eight Asian patients (five men and three women, aged 48 21 years) with systemic lupus erythematosus (SLE, n= from A to G. The CYP3A5 6986A allele is expresses the Fig. 1 The analysis results of genotypes *1/*1, *1/*3, *3/*3 in CYP3A5 using a fully automated gene analyzer, i-densy IS-5320, and a direct PCR sequencing method.
*1/*1 *1/*3 *3/*3 i-densy Direct sequencing Table 3 The blood concentration of tacrolimus and genetic polymorphisms of CYP3A5 and MDR1
Patient
Dose of tacrolimus Blood concentrations of tacrolimus . Table 3 shows the blood concentrations of tacrolimus and genotypes of CYP3A5 and MDR1 in the eight patients. Frequencies of genotypes of CYP3A5 were 1/ 1 in one, 1/ 3 in two, and 3/ 3 in five patients using both a fully automated gene analyzer, i-densy IS-5320, and a direct PCR sequencing method. Thus, it is essential to frequently monitor blood concentrations and establish an optimal dose.
Results
Orally administered tacrolimus is endocytosed rapidly to small-intestinal epithelia from the gastrointestinal lumen owing to its lipophilicity. A portion of it is metabolized by CYP3A4 and CYP3A5 and is subsequently inactivated. The endocytosed tacrolimus is excreted back to the luminal side of the epithelium by MDR1, which is a foreign-matter removal transporter existing in the smallintestinal epithelium. Furthermore, tacrolimus that enters systemically is metabolized by CYP3A4 and CYP3A5 in the liver, and the metabolites are excreted into the bile via MDR1 at the biliary lateral membrane (Fig. 2) 11 .
Thus, it is inferred that the genetic polymorphisms involving CYP3A4 and CYP3A5, as well as MDR1, influence the pharmacokinetics of tacrolimus.
In genetic polymorphisms of CYP3A5, CYP3A5 3 has a high frequency in Japanese populations. It is reported that the frequency of the allele in Japanese populations is about 56 64% in CYP3A5 3/ 3 (non-expresser) 12 . CYP3A 5 3/ 3 does not express CYP3A5 proteins and has low metabolic activity, resulting in easily maintained blood concentrations of tacrolimus. On the other hand, CYP3A5
1 has a high enzymatic activity for metabolizing tacrolimus (expresser). Therefore, a larger dose is required to maintain the blood concentration. Furthermore, it has been shown that the enzymatic activity of CYP3A5
1/ 1 as a homo-type is higher than that of 1/ 3 as a hetero-type 13 . In this study, in one patient with CYP3A5 1/ 1, blood concentrations of tacrolimus could not be detected even after oral administration at the maximum dose of 4 mg/day. In the two patients with CYP3A5 1/ 3, an increase in tacrolimus blood concentrations was not readily achieved in one patient, but increased favorably in the other patient. We showed the concomitant medications in all patients in Table 4 . Since all patients were taking many concomitant medications, influences of unknown mutual drug interactions could not be excluded.
This may be one reason why blood concentrations of tacrolimus are slightly different even in the same genetic polymorphism, as in patients 2 and 6.
As for MDR1, although genetic polymorphisms for 2677G and 3435C have been studied frequently, there have been mixed reports on the presence or absence of their influence on drug efficacy 14, 15 . Their frequencies, in Japanese populations, are reported to range from 15 20%
for 2677G/G, and from 25 30% for 3435C/C, respec- 16 . The results in this study were slightly higher, with 37.5% in 2677G/G, and 50% in 3435C/C, respectively. Due to the small number of patient, no apparent relationship between these genetic polymorphisms and blood concentrations of tacrolimus could be established.
Nevertheless, it is notable that in one patient whose blood concentration did not increase after administration of tacrolimus, both 2677G/G and 3435C/C were wild types with sufficient excreting functions. A larger cohort of patients is needed to further investigate this relationship in future studies.
In this study, analyses of genotypes in CYP3A5 and MDR1 were conducted within our hospital using a fully 
Conclusions
Measurement of genetic polymorphisms in metabolizing enzymes of tacrolimus, within one medical facility, is applicable for the selection of immunosuppressants and individual dosing for the treatment of autoimmune disease.
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